Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.
Who Can Benefit from Spravato?
Treatment-Resistant Depression (TRD)
Major Depressive Disorder with Suicidal Ideations
If you have major depressive disorder and have expressed suicidal thoughts or behaviors, Spravato® nasal spray may be an appropriate next step in treatment.
FAQ
Yes, Spravato (esketamine nasal spray) is generally covered by most insurance plans in the U.S., including Medicare and private insurers. However, coverage specifics can vary based on your insurance provider, plan type, and individual circumstances.
Yes, Spravato (esketamine) is now FDA-approved as a standalone treatment for adults with treatment-resistant depression (TRD).
Some of the common side effects of Spravato are dizziness, nausea, headache and can increase blood pressure.
Patients are not to eat for at least 2 hours before your treatment and are not to drink at least 30 minutes before your treatment.
